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Abstract
Background: Demyelinating diseases of the central nervous system associated with autoantibodies
against aquaporin-4 and myelin-oligodendrocyte-glycoprotein are mediated by different immunopatho-
logical mechanisms compared to multiple sclerosis.
Objective: The purpose of this study was to evaluate serum and cerebrospinal fluid cytokine/chemokine
profiles in patients with autoantibodies against aquaporin-4 or autoantibodies against myelin-
oligodendrocyte-glycoprotein-associated demyelination compared to multiple sclerosis and autoimmune
encephalitis.
Methods: Serum and cerebrospinal fluid cytokine/chemokine levels were analysed using Procartaplex
Multiplex Immunoassays. First, we analysed a panel of 32 cytokines/chemokines in a discovery group
(nine aquaporin-4-antibody seropositive, nine myelin oligodendrocyte glycoprotein-antibody seroposi-
tive, eight encephalitis, 10 multiple sclerosis). Significantly dysregulated cytokines/chemokines were
validated in a second cohort (11 aquaporin-4-antibody seropositive, 18 myelin oligodendrocyte
glycoprotein-antibody seropositive, 18 encephalitis, 33 multiple sclerosis).
Results: We found 11 significantly altered cytokines/chemokines in cerebrospinal fluid and serum
samples in the discovery group (a proliferation-inducing ligand, fractalkine¼CX3CL1, growth-
regulated oncogene-a, interleukin-1 receptor antagonist, interleukin-6, interleukin-8¼CXCL8,
interleukin-10, interleukin-21, interferon-Ç-induced protein-10¼CXCL10, monokine induced by inter-
feron-Ç¼CXCL9, macrophage inflammatory protein-1ß¼CCL4). Most of these cytokines/chemokines
were up-regulated in autoantibodies against aquaporin-4 or autoantibodies against myelin-
oligodendrocyte-glycoprotein positive patients compared to multiple sclerosis. We confirmed these
results for cerebrospinal fluid interleukin-6 and serum interleukin-8, growth-regulated oncogene-a, a
proliferation-inducing ligand and macrophage inflammatory protein-1b in the validation set. Receiver-
operating characteristic analysis revealed increased levels of cerebrospinal fluid interleukin-6, serum
interleukin-8 and growth-regulated oncogene-a in most patients with autoantibody-associated neurolog-
ical diseases.
Conclusion: This study suggests that distinctive cerebrospinal fluid and serum cytokine/chemokine
profiles are associated with autoantibody-mediated demyelination, but not with multiple sclerosis.
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Introduction
Autoimmune diseases of the central nervous system
(CNS) including aquaporin-4-antibody (AQP4-Ab)
seropositive neuromyelitis optica spectrum
disorders (NMOSDs), myelin oligodendrocyte
glycoprotein-antibody (MOG-Ab) disease
(AQP4-Ab seronegative NMOSD, optic neuritis
(ON), transverse myelitis (TM), encephalitis and
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acute disseminated encephalomyelitis (ADEM)),
anti-N-methyl-D-aspartate receptor-antibody
(NMDAR-Ab) encephalitis and multiple sclerosis
(MS) are characterised by complex interactions
between the innate and adaptive immune system.1–4
Over the last years, these non-infectious inflammatory
diseases have been the target of extensive research on
aetiopathogenic mechanisms and on diagnostic aids.
Autoantibodies targeting the astrocytic water channel
aquaporin-4 (AQP4) have emerged as a highly sensi-
tive and specific biomarker for the differentiation of
NMOSD from MS, which is a crucial issue for an
appropriate therapeutic choice.5 In fact, several MS
treatments, such as interferon (IFN)-b, natalizumab
and fingolimod, could lead to exacerbation of the
NMOSD disease course, supporting the idea that
NMOSD is distinct fromMSand thatNMOSD is dom-
inated by humoral mechanisms. However, not all
patients presenting with clinical features suggestive
of a NMOSD disease phenotype are seropositive for
AQP4-Ab and up to 50% of those patients are sero-
positive for MOG-Ab.3 Despite overlapping clinical
presentations, multiple lines of data including (a) a
lower proportion of females, (b) higher predominance
of amonophasic disease course and (c) better function-
al recovery and steroid responsiveness in MOG-Ab
positive patients indicate that AQP4-Ab and MOG-
Ab diseases might have a different underlying patho-
genesis and are distinct demyelinating conditions.3
Along these lines, specific molecular profiles may
give some cues to the pathogenesis and aetiology of
CNS inflammation useful for stratifying different clin-
ical conditions and guiding novel treatment strategies.
Previous reports demonstrated that T helper (Th)-17-
and Th2-associated cytokines are up-regulated in
patients with NMOSD, whereas MS is primarily a
Th1-dominant disease suggesting that cytokine/cheo-
kine profiles in NMOSD are different from MS.6–8 A
recent study underpins this assumption by showing
that the CSF cytokine profile in MOG-Ab disease is
similar to AQP4-immunoglobulin (Ig)-G positive
NMOSD but clearly distinct from MS.9 Among the
Th17-axis cytokines, specific attention has been
recently devoted to interleukin (IL)-6, which is
involved in tissue regeneration, inflammation and
defence against pathogens with a central role in
CNS neuroinflammatory pathways.10 High levels of
IL-6 have been particularly reported in the CSF of
AQP4-Ab NMOSD patients, suggesting that this bio-
marker might be a predictor of disease severity.6,11,12
Increased IL-6 levels in the CSF have been also
described in MOG-Ab disease and in subjects with
various forms of viral or autoimmune encephalitis,
in particular in those with NMDAR-Ab.13–15 In light
of these observations, blockade of IL-6 receptor sig-
nalling has been suggested as a possible therapeutic
strategy in severe cases of AQP4-Ab and MOG-Ab
disease as well as autoimmune encephalitis refractory
to conventional immunotherapies.16–21
Therefore, the main aim of this study was to evaluate
cytokine/chemokine profiles, with a particular focus
on IL-6, in paired serum and CSF samples of
patients in the acute phase of AQP4-Ab and MOG-
Ab-associated CNS demyelinating diseases in com-
parison to MS and anti-NMDAR encephalitis and to
unravel their utility as biomarkers to distinguish Ab-
mediated conditions from MS.
Material and methods
Study subjects and clinical data
Serum and CSF samples were collected and stored at
three diagnostic centres (Neuropathology Laboratory,
University Hospital of Verona, Italy; Clinical
Department of Neurology, Medical University of
Innsbruck, Austria; Institute of Neurology, Medical
University of Vienna, Austria) between 2009–2018.
This study was approved by the Ethical Committee of
the University of Verona (study number 1052CESC),
the Medical University of Innsbruck (study numbers
AM3041A and AM4059) and the Medical University
of Vienna (study number EK1123/2015). All avail-
able samples from patients from the three diagnostic
centres in Austria (Innsbruck, Vienna) and Italy
(Verona) were included. All samples were collected
during the diagnostic uptake (median disease duration
2.5 months, range 0–264 months) in the acute phase.
Patients or their caregivers gave written informed con-
sent to diagnostic procedures and biological sample
storage. The discovery group was represented by
nine AQP4-Ab patients (nine females, age 42–83
years), nine subjects with MOG-Ab disease (five
females and four males, age 4–51 years), eight anti-
NMDAR encephalitis cases (six females and two
males, age 3–56 years) and 10 MS patients (five
females and five males, age 24–51 years) (Figure 1
(a)). The validation group consisted of 11 AQP4-Ab
patients (10 females and one male, age 19–76 years),
18 subjects with MOG-Ab disease (eight females and
10 males, age 1–68 years), 18 anti-NMDAR encepha-
litis cases (nine females and nine males, age 7–42
years) and 33 MS patients (18 females and 15
males, age 20–74 years) (Figure 1(b)).
All patients with CNS disorders were classified
according to specific diagnostic criteria into four
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categories: (a) NMOSD, (b) MS, (c) other demye-
linating conditions including ADEM, idiopathic ON,
idiopathic myelitis and idiopathic inflammatory dis-
orders and (d) anti-NMDAR-encephalitis.5,22–24
Idiopathic ON and/or myelitis were defined as one
or more episodes of acute/subacute optic neuropathy
and/or myelopathy of inflammatory origin (based on
clinical, radiological and/or CSF evidence) not ful-
filling diagnostic criteria for MS, NMOSD and
ADEM and not attributable to other causes. The
cohort was mainly composed of adults. Of all includ-
ed patients (116) from both cohorts 11/27 (41%)
MOG-Ab positive cases and 7/26 (27%) patients
with NMDAR-Ab were children, whereas the
AQP4-Ab and MS groups only included adults.
AQP4-Ab, MOG-Ab and NMDAR-Ab detec-
tion assays
Serum AQP4-Ab and serum/CSF NMDAR-Ab were
analysed using commercially available cell-based
assays (Euroimmun, Luebeck, Germany) according
to the manufacturer’s instructions or by live cell- or
tissue-based assays.25
Serum MOG-Ab was analysed using recombinant
live cell-based immunofluorescence assay with
HEK293A cells transfected with full-length MOG
(human MOG alpha-1 enhanced green fluorescent
protein (EGFP) fusion protein), as described previ-
ously.25 Sera were tested at dilutions of 1:20 and
1:40 and MOG-Ab positivity was titrated with
serial dilutions with a threshold of 1:160 to define
MOG-Ab positivity.
Cytokine and chemokine immunoassays
Levels of cytokines/chemokines in serum and CSF
pairs of patients of the discovery group were deter-
mined using a commercially available custom 32-
plex Procartaplex Multiplex Immunoassay
(Thermo Fisher Scientific, Waltham, MA, USA;
Figure 1. Demographic characteristics of participants from the (a) discovery and (b) validation group.
Ab: antibody; AQP-4: aquaporin-4; F: female; M: male; MOG: myelin oligodendrocyte glycoprotein; MS: multiple
sclerosis; NMDAR: N-methyl-D-aspartate receptor; NMOSD: neuromyelitis optica spectrum disorder.
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cat.#: PPX-32-MXCE33Y) according to the manu-
facturer’s instructions. This magnetic bead assay is
based on the Luminex xMAP technology, which
enables the simultaneous detection and quantitation
of multiple secreted cytokines/chemokines,
namely: a proliferation-inducing ligand (APRIL),
B cell activating factor (BAFF), B lymphocyte
chemoattractant (BLC) or CXC-chemokine ligand
(CXCL)-13, CD40 ligand (CD40L), eotaxin or
CC-chemokine ligand (CCL)-11, fractalkine or
CX3C-chemokine ligand (CX3CL)-1, granulocyte
colony-stimulating factor (G-CSF) or CSF-3, gran-
ulocyte macrophage colony-stimulating factor
(GM-CSF), growth-regulated oncogene (GRO)-a
or KC/CXCL1, IFN-a, IFN-Ç, IL-1b, IL-1
receptor antagonist (RA), IL-2, IL-4, IL-5, IL-6,
IL-8 (CXCL8), IL-10, IL-12p70, IL-13, IL-17A
or cytotoxic T-lymphocyte-associated protein
(CTLA)-8, IL-21, IL-23, IFN-Ç-induced protein
(IP)-10 or CXCL10, monocyte chemoattractant
protein (MCP)-1 or CCL2, monokine induced by
interferon-Ç (MIG) or CXCL9, macrophage
inflammatory protein (MIP)-1a or CCL3, MIP-1b
(CCL4), MIP-3a (CCL20), stromal cell-derived
factor (SDF)-1a, tumour necrosis factor (TNF)-a
(Supplementary Material Table 1). Next, levels
of cytokines/chemokines in serum and CSF pairs
of 80 patients of the validation group were inves-
tigated using Procartaplex Human Basic Kits
(Thermo Fisher Scientific, Waltham,
Massachusetts, USA; cat.#: EPX010-10420-901)
combining six and five different cytokine/chemo-
kine beads that were found to be significantly
dysregulated in the discovery group, namely
APRIL, GRO-a, MIP-1b, IL-1RA, IL-6, IL-
8 (Standard-Mix A Lot#162779101, Standard-Mix
B Lot#149689000. Standard-Mix K
Lot#:124478000) and fractalkine, IL-10, IL-21,
IP-10, MIG (Standard-Mix A Lot#180560101,
Standard-Mix B Lot#182229101, Standard-Mix D
Lot#140146301), respectively (Supplementary
Material Table 1).
Multiplex assays were performed according to the
manufacturer’s instructions. Briefly, magnetic
beads at working concentration were added into
each well of the kit-provided black 96-well flat
bottom plates. After washing of the beads and
removal of any residual liquid, samples, standards
and blanks were added. For serum and CSF pairs,
25 ll of the kit-provided 1 Universal Assay
Buffer was added to each well followed by 25
ll four-fold serial diluted standards or undiluted
samples into dedicated wells. For wells designated
as blanks, additional 25 ll Buffer was added. The
plate was incubated for 30 min with agitation at
300 rounds per min (rpm) at room temperature
(RT) and protection from light exposure.
Afterwards, the plate was transferred on a level
surface at 4C. After overnight incubation, the
plate was again shaken at 300 rpm for 30 min
at RT and then the magnetic beads were washed.
Next, 25 ll of 1 Detection Antibody Mixture was
added to each well and incubated for 30 min with
agitation at 300 rpm at RT and light protection.
After washing of magnetic beads, 50 ll of
streptavidin-phycoerythrin (SAPE) solution was
added and incubated for 30min as described
above. After another washing step, the test plate
was prepared for analysis on a Luminex instru-
ment by adding 120 ll of Reading Buffer into
each well and incubation with agitation at 300
rpm for five minutes at RT. Finally, the plate
was analysed on the Luminex MAGPIX instrument
(Software: xPonent 4.2). The cytokine/chemokine
concentrations were calculated using the standard
curve generated by the five-parameter logistic
regression method. In samples where cytokines/
chemokines were undetectable, the values of the
detection limit were used for analyses.
Statistical analysis
Statistical analyses were performed using IBM SPSS
software (IBM Corp. Released 2012. IBM SPSS
Statistics; Version 21.0. Armonk, New York, USA:
IBM Corp.) and GraphPad Prism 7 (GraphPad
Software, La Jolla, California, USA). The null
hypothesis (H0) for the 32-plex discovery experi-
ment was that none of the serum or CSF cyto-
kines/chemokines were significantly different
between the four groups. Overall significance was
assessed using the nonparametric Kruskal Wallis
test and p-values were adjusted for multiple compar-
isons using a false discovery rate (FDR) significance
criterion of 10% based on the Benjamini-Hochberg
correction. Between-group comparisons were calcu-
lated using Dunn’s multiple comparison test. Eleven
dysregulated cytokines/chemokines were then con-
firmed in the validation group and statistical analysis
was done as described above. Receiver-operating
characteristic (ROC) analysis was performed on
pooled samples to determine cut-off values for cyto-
kines/chemokines dysregulated in both data sets.
Correlation coefficients of the five significantly dys-
regulated cytokines/chemokines between CSF and
serum were evaluated using the Spearman’s rho cor-
relation test.
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Results
Significantly altered cytokine and chemokine
profiles in CSF and serum samples from patients
with neuroinflammatory disorders
First, we have analysed the levels of 32 different
cytokines/chemokines in paired CSF and serum sam-
ples from the discovery group (Figure 1(a),
Supplementary Material Table 1). In this discovery
cohort the levels of three cytokines/chemokines
(IL-6, IL-8 and GRO-a) were significantly different
between groups in the CSF and 10 cytokines/chemo-
kines (IL-1RA, fractalkine, MIG, MIP-1b, IP-10,
APRIL, IL-21, IL-8, IL-10 and GRO-a; cytokines/
chemokines organised according to their p-values)
were significantly different in the serum (Figure 2,
Supplementary Material Material Figure 1).
In a next step, the 11 most significantly dysregulated
cytokines/chemokines (APRIL, fractalkine, GRO-a,
MIG, MIP-1b, IL-1RA, IL-6, IL-8, IL-10, IL-21 and
IP-10) were validated in paired CSF and serum sam-
ples from the validation group (Figure 1(b),
Supplementary Material Table 1). In this confirmatory
analysis the levels of six cytokines/chemokines (IL-6,
fractalkine, MIP-1b, IL-21, MIG and IP-10) were sig-
nificantly different between groups in the CSF and five
cytokines/chemokines (IL-8, GRO-a, IL-6, APRIL and
MIP-1b; cytokines/chemokines organised according to
their p-values) were significantly different in the serum
(Figure 3, Supplementary Material Figure 1). Thus, we
could confirm the results from the discovery experi-
ment for CSF IL-6 and serum IL-8, GRO-a, APRIL
and MIP-1b.
CSF IL-6 and serum IL-8, GRO-a, APRIL and
MIP-1b are predictors of antibody-
mediated conditions
In a final step we have pooled and analysed the data
from both experiments for the five significantly dys-
regulated cytokines/chemokines in either the CSF or
serum in order to evaluate, which of the CSF and/or
serum cytokines/chemokines were the best predic-
tors of antibody-mediated conditions. Using ROC
analysis, we calculated area under the curve
(AUC) values and determined cut-off values of
CSF IL-6 and of serum IL-8, GRO-a, APRIL and
MIP-1b to discriminate AQP4-Ab, MOG-Ab and
NMDAR-Ab from MS patients with 95% specificity
(Figure 4, Table 1) Serum IL-8 level 3.7 pg/ml had
the highest sensitivity (77%) for AQP4-Ab and
MOG-Ab-associated demyelinating diseases, fol-
lowed by serum GRO-a (cut-off 7.2 pg/ml, sensi-
tivity 70%) and CSF IL-6 (cut-off 17.6 pg/ml,
sensitivity 47%). When combining the cut-off
values for serum IL-8 and GRO-a, none of the MS
patients, but 60% of AQP4-Ab positive patients and
63% of MOG-Ab positive patients had increased
values. However, this increased serum cytokine/che-
mokine response was not specific for AQP4-Ab and
MOG-Ab-associated demyelinating diseases, but
also seen in anti-NMDAR encephalitis (77%) indi-
cating a common inflammatory response in antibody
(Ab)-associated neurological autoimmune diseases,
which is not observed in MS.
Moreover, correlations of the five significantly dys-
regulated cytokines/chemokines between CSF and
serum were evaluated (Table 2). In MS patients, sig-
nificant correlations were found for the Th17-related
cytokine IL-6 and for the B cell-related cytokine
APRIL. In MOG-Ab positive patients, significant
correlations were observed for the broad spectrum-
related chemokine MIP-1ß.
Finally, we have analysed possible clinical associa-
tions for these cut-off values. Due to the retrospec-
tive character of our study, the data set is incomplete
and only allows an explanatory analysis. As can be
seen from Supplementary Material Tables 2–4 there
were no statistically significant differences for age,
sex, clinical presentation or diagnosis, neither over-
all nor for the MOG-Ab and AQP4-Ab subgroups.
There was a tendency (p<0.1) for a higher frequency
of myelitis in patients with increased CSF IL-6
levels in both subgroups and for increased serum
GRO-a levels in MOG-Ab positive children. CSF
cell counts and CSF protein levels were significantly
increased in patients with increased CSF IL-6 levels,
overall and in the MOG-Ab subgroup.
Discussion
It has been suggested that cytokine/chemokine pro-
files may reflect distinct immunopathological pro-
cesses between Ab-associated conditions and MS.
They might not only be important for a better under-
standing of the pathophysiology of these syndromes,
but may also prove as useful biomarkers for stratifi-
cation of patients, which is a prerequisite for the
appropriate treatment choice. We found significantly
increased levels of the Th17-related cytokine IL-6 in
the CSF as well as IL-8 (Th17-related), APRIL (B
cell-related), GRO-a and MIP-1b (broad spectrum-
related) in the serum of patients with AQP4-Ab,
MOG-Ab and NMDAR-Ab as compared to MS,
which we could confirm in a validation set.
Additionally, ROC analysis from the combined dis-
covery and validation cohort revealed significantly
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Figure 2. Scatter dot plots of cytokines and chemokines in cerebrospinal fluid (CSF) and serum of the discovery set. Individual values for
aquaporin-4-antibody (AQP4-Ab), myelin oligodendrocyte glycoprotein-antibody (MOG-Ab), anti-N-methyl-D-aspartate receptor-antibody
(NMDAR-Ab) and multiple sclerosis (MS) patients are shown as circles and medians are shown as bars. Cytokines and chemokines are organised
according to their p-values. Overall significance was assessed using the nonparametric Kruskal-Wallis test and p-values were adjusted for multiple
comparisons using a false discovery rate (FDR) significance criterion of 10% based on the Benjamini-Hochberg correction. Between group
comparisons were calculated using Dunn’s multiple comparison test. Significant changes in the CSF (AQP4-Ab and MOG-Ab versus MS) and
serum (AQP4-Ab, MOG-Ab and NMDAR-Ab versus MS) are shown in the graphs.
Ab: antibody; AQP-4: aquaporin-4; APRIL: a proliferation-inducing ligand; BAFF: B cell activating factor; BLC: B lymphocyte chemoattractant;
G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte macrophage colony-stimulating factor; GRO: growth-regulated oncogene;
IFN: interferon; IL: interleukin; IP: interferon-Ç-induced protein; MCP: monocyte chemoattractant protein; MIG: monokine induced by inter-
feron-Ç; MIP: macrophage inflammatory protein; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; NMDAR: N-methyl-D-
aspartate receptor; ns: not significant; SDF: stromal cell-derived factor; TNF: tumour necrosis factor.
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Figure 3. Scatter dot plots of cytokines and chemokines in cerebrospinal fluid (CSF) and serum of the validation set. Individual values for
aquaporin-4-antibody (AQP4-Ab), myelin oligodendrocyte glycoprotein-antibody (MOG-Ab), anti-N-methyl-D-aspartate receptor-antibody
(NMDAR-Ab) and multiple sclerosis (MS) patients are shown as circles and medians are shown as bars. Cytokines and chemokines are organised
according to their p-values. Overall significance was assessed using the nonparametric Kruskal Wallis test and p-values were adjusted for multiple
comparisons using a false discovery rate (FDR) significance criterion of 10% based on the Benjamini-Hochberg correction. Between group
comparisons were calculated using Dunn’s multiple comparison test. Significant changes in the CSF (AQP4-Ab and MOG-Ab versus MS) and
serum (AQP4-Ab, MOG-Ab and NMDAR-Ab versus MS) are shown in the graphs.
Ab: antibody; AQP-4: aquaporin-4; GRO: growth-regulated oncogene; IL: interleukin; IP: interferon-Ç-induced protein; MCP: monocyte che-
moattractant protein; MIG: monokine induced by interferon-Ç; MIP: macrophage inflammatory protein; MOG: myelin oligodendrocyte glyco-
protein; MS: multiple sclerosis; NMDAR: N-methyl-D-aspartate receptor; ns: not significant.
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Figure 4. Dysregulated cytokines and chemokines confirmed in both cohorts. Pooled individual values for both cohorts are shown as circles and
medians are shown as bars. Significance of group differences was analysed by the Kruskal Wallis test and significant differences (p-value <0.001)
are shown by the asterisks.
The grey dashed lines represent the cut-off value of CSF IL-6 (a) and of serum IL-8 (b), GRO-a (d), APRIL (d) and MIP-1b (d) to discriminate
AQP4-Ab, MOG-Ab and NMDAR-Ab from MS patients with 95% specificity.
Ab: antibody; APRIL: a proliferation-inducing ligand; AQP-4: aquaporin-4; CSF: cerebrospinal fluid; GRO: growth-regulated oncogene; IL:
interleukin; MIP: macrophage inflammatory protein; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; NMDAR: N-methyl-D-
aspartate receptor.
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increased levels of those five cytokines/chemokines
in Ab-mediated conditions suggesting that they are
predictors of Ab-associated diseases clearly distinc-
tive from MS. Although we did not find significantly
altered serum IL-6 levels in the discovery set, serum
IL-6 levels were significantly increased in the vali-
dation set but also in pooled data from both experi-
ments. In this regard, IL-6, the key polarising
cytokine of Th17 cells, has pleiotropic effects medi-
ated through the transmembrane protein gp130
including modulation of nociceptive neurons associ-
ated with pain, T and B cell activation, Th17 differ-
entiation, immunoglobulin synthesis as well as
plasmablast survival.10,26 Thus, these findings
might be explained by the critical IL-6 involvement
in the activation and maintenance of humoral
responses and might also indicate active cooperation
of Th17 and B cells in the immunopathogenicity of
Ab-mediated inflammatory disorders.26
Significantly higher levels of APRIL in the serum
of Ab-mediated conditions, which is a crucial plas-
mablast factor regulating B cell survival, differenti-
ation and class switching underpin this
interrelation.27 Additionally, up-regulation of
Th17-related (IL-8) and broad spectrum-related che-
mokines (GRO-a, MIP-1b) with potent chemoattrac-
tant properties in the serum of patients with Ab-
associated conditions might add to these pathologi-
cal processes by recruiting inflammatory cells such
as neutrophils to targeted sites.28 In this context, as
proposed in AQP4-Ab positive cases, IL-6 signalling
might facilitate Ab accumulation in the target sites
promoting Ab-mediated autoimmunity, and might
also cause a decrease in blood brain barrier (BBB)
function, an increase in chemokine production
resulting in enhanced leukocyte transmigration.29,30
While controversial data have been reported on
serum IL-6 levels in NMOSD patients, more recent
findings confirm the significant elevation of CSF
IL-6 concentration in this condition, suggesting
that this biomarker might be potentially used to dif-
ferentiate NMOSD from MS.11,31,32 Moreover, up to
now, only a few studies have analysed IL-6 levels in
the biological fluids of subjects with conditions
related to MOG-Ab and all focused on CSF
values.9,15,33 According to these reports, MOG-Ab
Table 1. Receiver-operating characteristic (ROC) analysis of dysregulated cytokines and chemokines.
Variable
Area under the curve
(95% CI) p-Value
Cut-off
(pg/ml) AQP4-Ab MOG-Ab NMDAR-Ab MS
CSF IL-6 0.887 (0.818–0.956) <0.001 17.6 12/20 (60%) 15/27 (56%) 7/26 (27%) 2/43 (5%)
Serum IL-8 0.936 (0.886–0.989 <0.001 3.7 17/20 (85%) 18/27 (67%) 21/26 (81%) 2/43 (5%)
Serum GROa 0.874 (0.799–0.950) <0.001 7.2 12/20 (60%) 19/27 (70%) 20/26 (77%) 2/43 (5%)
Serum APRIL 0.857 (0.775–0.939) <0.001 5339.6 3/20 (15%) 5/27 (18%) 12/26 (46%) 2/43 (5%)
Serum MIP-1ß 0.791 (0.697–0.885) <0.001 174.2 2/20 (10%) 6/27 (22%) 10/26 (38%) 2/43 (5%)
Ab: antibody; APRIL: a proliferation-inducing ligand; AQP-4: aquaporin-4; CI: confidence interval; CSF: cerebrospinal fluid; GRO: growth-
regulated oncogene; IL: interleukin; MIP: macrophage inflammatory protein; MOG: myelin oligodendrocyte glycoprotein; MS: multiple
sclerosis; NMDAR: N-methyl-D-aspartate receptor.
Table 2. Correlation of dysregulated cytokines and chemokines between cerebrospinal fluid (CSF) and serum.
Variable
Overall
(n¼116) rs
AQP4-Ab
(n¼20) rs
MOG-Ab
(n¼27) rs
NMDAR-Ab
(n¼26) rs
MS
(n¼43) rs
IL-6a 0.510b –0.200 0.188 0.308 0.465b
IL-8a 0.126 –0.078 0.180 –0.257 0.061
GRO-aa 0.048 0.119 –0.199 0.031 0.000
APRILa 0.201c 0.047 –0.088 0.006 0.447b
MIP-1ßa 0.435b 0.077 0.535b 0.213 0.046
Ab: antibody; APRIL: a proliferation-inducing ligand; AQP-4: aquaporin-4; GRO: growth-regulated oncogene; IL: interleukin; MIP: mac-
rophage inflammatory protein; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; NMDAR: N-methyl-D-aspartate receptor.
aCorrelation coefficients (rs) were analysed using Spearman’s rho correlation test.
bSignificant correlations p0.01 and csignificant correlations p0.05 of dysregulated cytokines and chemokines between CSF and serum.
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positive patients seem to have higher CSF IL-6
levels than seronegative patients, which also corre-
lates with MOG-Ab titres.15,33 Currently, tocilizu-
mab, a humanised monoclonal antibody targeting
the IL-6 receptor (IL-6R) and approved for the treat-
ment of rheumatoid arthritis has been successfully
used as off-label therapy to effectively reduce
relapse rate and disability, neuropathic pain and gen-
eral fatigue in AQP4-Ab positive NMOSD and is
suggested as a third-line treatment in severe and
treatment-resistant cases.34 But also recent reports
in MOG-Ab-associated diseases and autoimmune
encephalitis have shown promising effects in patients
having failed various immunotherapies including rit-
uximab, which is a B-cell depleting therapy.17,20,21
Similar to disease exacerbation of NMOSD patients
in response to MS treatments, it has been reported
that anti-IL-6R blockade might pose a risk to cause
MS-like demyelinating disorders.35 However, in line
with the immunological and biological differences in
Ab-mediated conditions and MS, which we could also
observe in our study, this might rather relate to differ-
ent underlying pathophysiological processes involved
in these diseases. These data also suggest that the IL-6
pathway may be spared in MS and underline the rel-
evance of different pathogenic mechanisms in induc-
ing the associated immune response. It might seem
surprising to find a similar cytokine profile for Ab-
associated demyelinating diseases and anti-NMDAR-
Ab encephalitis, despite different clinical courses and
antigenic targets. These conditions are all characterised
by a specific contribution of humoral responses and
autoantibody production. A possible explanation could
be that the immunological processes for the generation
of autoantibodies are virtually the same, while the
affected biological target determines the clini-
cal phenotype.
The main limitation of our study is its retrospective
character and the incomplete clinical documentation
of included cases. Therefore, our study should be con-
sidered as a pilot study, which informs the scientific
community about our results and fosters confirmatory
prospective studies to establish novel biomarkers for
Ab-associated demyelinating disorders.
In conclusion, we found a distinctive cytokine/che-
mokine profile in Ab-associated conditions com-
pared to MS. Especially, IL-6 constitutes not only
an important biomarker of Ab-mediated inflamma-
tory CNS diseases but also represents an important
therapeutic target in NMOSD. Furthermore, our
observation that increased serum IL-8 and GRO-a
were absent in MS patients, but present in 60% of
AQP4-Ab positive patients and 63% of MOG-Ab
positive patients might be helpful to establish
novel diagnostic biomarkers for these syndromes.
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